Stay updated on TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial
Sign up to get notified when there's something new on the TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial page.

Latest updates to the TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded new study identifiers KEYNOTE-E10, MK-3475-E10, and jRCT2061220066; removed MK3475-C73 and updated the registry labeling.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision: v3.4.3 was added, replacing v3.4.2 in the page's release notes.SummaryDifference0.0%

- Check41 days agoChange DetectedAdded detailed primary objectives (PFS/OS) and endpoint definitions (ORR, DoR, DCR, PFS, OS) along with TROP2 NMR assessment and IPD data-sharing information. Removed or altered several earlier endpoint definitions, time frames, and explicit eligibility criteria.SummaryDifference0.7%

- Check48 days agoChange DetectedRevision: v3.4.2 was added and Revision: v3.4.1 was removed, a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page now shows Revision: v3.4.1 and the government funding notice and Revision: v3.4.0 have been removed.SummaryDifference0.1%

- Check62 days agoChange DetectedSite-wide notice informs users that information may not be up to date due to a lapse in government funding and that the NIH Clinical Center is open, with operating-status updates linked. This change does not affect the study content, eligibility criteria, or trial results on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial page.